{"generic":"Sulfadiazine","drugs":["Sulfadiazine"],"mono":{"0":{"id":"cba2s0","title":"Generic Names","mono":"Sulfadiazine"},"1":{"id":"cba2s1","title":"Dosing and Indications","sub":[{"id":"cba2s1b4","title":"Adult Dosing","mono":"<ul><li>a 5-day  and a 10-day  sulfADIAZINE desensitization regimens in AIDS patients has been presented<\/li><li><b>Acute otitis media, Due to Haemophilus influenzae, in combination with penicillin:<\/b> initial, 2 to 4 g ORALLY<\/li><li><b>Acute otitis media, Due to Haemophilus influenzae, in combination with penicillin:<\/b> maintenance, 2 to 4 g ORALLY divided into 3 to 6 doses, every 24 hours<\/li><li><b>Chancroid:<\/b> initial, 2 to 4 g ORALLY<\/li><li><b>Chancroid:<\/b> maintenance, 2 to 4 g ORALLY divided into 3 to 6 doses, every 24 hours<\/li><li><b>Haemophilus influenzae meningitis, In combination with parenteral streptomycin; Adjunct:<\/b> initial, 2 to 4 g ORALLY<\/li><li><b>Haemophilus influenzae meningitis, In combination with parenteral streptomycin; Adjunct:<\/b> maintenance, 2 to 4 g ORALLY divided into 3 to 6 doses, every 24 hours<\/li><li><b>HIV infection - Toxoplasmosis; Prophylaxis:<\/b> secondary prophylaxis (preferred regimen), 2000 to 4000 mg ORALLY daily in 2 to 4 divided doses plus pyrimethamine 25 to 50 mg ORALLY daily plus leucovorin 10 to 25 mg ORALLY daily<\/li><li><b>HIV infection - Toxoplasmosis; Prophylaxis:<\/b> secondary prophylaxis (alternative regimen), 2000 to 4000 mg ORALLY daily in 2 to 4 divided doses plus atovaquone 750 mg ORALLY every 6 to 12 hour<\/li><li><b>Inclusion conjunctivitis:<\/b> initial, 2 to 4 g ORALLY<\/li><li><b>Inclusion conjunctivitis:<\/b> maintenance, 2 to 4 g ORALLY divided into 3 to 6 doses, every 24 hours<\/li><li><b>Malaria, due to chloroquine-resistant strains of Plasmodium falciparum; Adjunct:<\/b> initial, 2 to 4 g ORALLY<\/li><li><b>Malaria, due to chloroquine-resistant strains of Plasmodium falciparum; Adjunct:<\/b> maintenance, 2 to 4 g ORALLY divided into 3 to 6 doses, every 24 hours<\/li><li><b>Meningococcal meningitis; Treatment and Prophylaxis:<\/b> initial, 2 to 4 g ORALLY<\/li><li><b>Meningococcal meningitis; Treatment and Prophylaxis:<\/b> maintenance, 2 to 4 g ORALLY divided into 3 to 6 doses, every 24 hours<\/li><li><b>Nocardiosis:<\/b> initial, 2 to 4 g ORALLY<\/li><li><b>Nocardiosis:<\/b> maintenance, 2 to 4 g ORALLY divided into 3 to 6 doses, every 24 hours<\/li><li><b>Rheumatic fever, Recurrent; Prophylaxis:<\/b> (greater than 27 kg) 1 g ORALLY once a day; (27 kg or less) 500 mg ORALLY once a day (guideline dosing)<\/li><li><b>Rheumatic fever, Recurrent; Prophylaxis:<\/b> initial, 2 to 4 g ORALLY (manufacturer dosing)<\/li><li><b>Rheumatic fever, Recurrent; Prophylaxis:<\/b> maintenance, 2 to 4 g ORALLY divided into 3 to 6 doses, every 24 hours (manufacturer dosing)<\/li><li><b>Toxoplasma encephalitis:<\/b> (with\/without HIV) initial 2 to 4 g ORALLY (manufacturer dosing)<\/li><li><b>Toxoplasma encephalitis:<\/b> (with\/without HIV) maintenance, 2 to 4 g ORALLY divided into 3 to 6 doses, every 24 hours (manufacturer dosing)<\/li><li><b>Toxoplasma encephalitis:<\/b> (HIV) preferred therapy (less than 60 kg), 1000 mg ORALLY every 6 hour plus pyrimethamine 200 mg ORALLY for 1 dose, then 50 mg ORALLY daily plus leucovorin 10 to 25 mg (can increase to 50 mg) ORALLY daily for at least 6 week (guideline dosing)<\/li><li><b>Toxoplasma encephalitis:<\/b> (HIV) preferred therapy (60 kg or greater), 1500 mg ORALLY every 6 hour plus pyrimethamine 200 mg ORALLY for 1 dose, then 75 mg ORALLY daily plus leucovorin 10 to 25 mg (can increase to 50 mg) ORALLY daily for at least 6 week (guideline dosing)<\/li><li><b>Toxoplasma encephalitis:<\/b> (HIV) alternative therapy, 1000 to 1500 mg ORALLY every 6 hour plus atovaquone 1500 mg orally twice daily for at least 6 week (guideline dosing)<\/li><li><b>Trachoma:<\/b> initial, 2 to 4 g ORALLY<\/li><li><b>Trachoma:<\/b> maintenance, 2 to 4 g ORALLY divided into 3 to 6 doses, every 24 hours<\/li><li><b>Urinary tract infectious disease:<\/b> initial, 2 to 4 g ORALLY<\/li><li><b>Urinary tract infectious disease:<\/b> maintenance, 2 to 4 g ORALLY divided into 3 to 6 doses, every 24 hours<\/li><\/ul>"},{"id":"cba2s1b5","title":"Pediatric Dosing","mono":"<ul><li>use contraindicated in patients less than 2 months of age (except as adjunctive therapy in the treatment of congenital toxoplasmosis)<\/li><li><b>Acute otitis media, Due to Haemophilus influenzae, in combination with penicillin:<\/b> (2 months and older) initial 75 mg\/kg or 2 g\/m(2) ORALLY<\/li><li><b>Acute otitis media, Due to Haemophilus influenzae, in combination with penicillin:<\/b> (2 months and older) maintenance, 150 mg\/kg\/day or 4 g\/m(2)\/day ORALLY divided into 4 to 6 doses, every 24 hours; MAX 6 g every 24 hours<\/li><li><b>Chancroid:<\/b> (2 months and older) initial 75 mg\/kg or 2 g\/m(2) ORALLY<\/li><li><b>Chancroid:<\/b> (2 months and older) maintenance, 150 mg\/kg\/day or 4 g\/m(2)\/day ORALLY divided into 4 to 6 doses, every 24 hours; MAX 6 g every 24 hours<\/li><li><b>Congenital toxoplasmosis; Adjunct:<\/b> (2 months and older) initial 75 mg\/kg or 2 g\/m(2) ORALLY (manufacturer dosing)<\/li><li><b>Congenital toxoplasmosis; Adjunct:<\/b> (2 months and older) maintenance, 150 mg\/kg\/day or 4 g\/m(2)\/day ORALLY divided into 4 to 6 doses, every 24 hours; MAX 6 g every 24 hours (manufacturer dosing)<\/li><li><b>Congenital toxoplasmosis; Adjunct:<\/b> (HIV) 50 mg\/kg per dose ORALLY twice daily PLUS pyrimethamine 2 mg\/kg ORALLY once daily for 2 days, then 1 mg\/kg ORALLY once daily for 2 to 6 months, then 1 mg\/kg ORALLY 3 times weekly PLUS leucovorin 10 mg ORALLY or IM with each dose of pyrimethamine; total treatment duration is 12 months (guideline dosing)<\/li><li><b>Haemophilus influenzae meningitis, In combination with parenteral streptomycin; Adjunct:<\/b> (2 months and older) initial 75 mg\/kg or 2 g\/m(2) ORALLY<\/li><li><b>Haemophilus influenzae meningitis, In combination with parenteral streptomycin; Adjunct:<\/b> (2 months and older) maintenance, 150 mg\/kg\/day or 4 g\/m(2)\/day ORALLY divided into 4 to 6 doses, every 24 hours; MAX 6 g every 24 hours<\/li><li><b>HIV infection - Toxoplasmosis; Prophylaxis:<\/b> secondary prophylaxis, 85 to 120 mg\/kg\/day (MAX 2 to 4 g) ORALLY divided into 2 to 4 doses PLUS pyrimethamine 1 mg\/kg or 15 mg\/m(2) (MAX 25 mg) ORALLY daily PLUS leucovorin 5 mg ORALLY every 3 days<\/li><li><b>Inclusion conjunctivitis:<\/b> (2 months and older) initial 75 mg\/kg or 2 g\/m(2) ORALLY<\/li><li><b>Inclusion conjunctivitis:<\/b> (2 months and older) maintenance, 150 mg\/kg\/day or 4 g\/m(2)\/day ORALLY divided into 4 to 6 doses, every 24 hours; MAX 6 g every 24 hours<\/li><li><b>Malaria, due to chloroquine-resistant strains of Plasmodium falciparum; Adjunct:<\/b> (2 months and older) initial 75 mg\/kg or 2 g\/m(2) ORALLY<\/li><li><b>Malaria, due to chloroquine-resistant strains of Plasmodium falciparum; Adjunct:<\/b> (2 months and older) maintenance, 150 mg\/kg\/day or 4 g\/m(2)\/day ORALLY divided into 4 to 6 doses, every 24 hours; MAX 6 g every 24 hours<\/li><li><b>Meningococcal meningitis; Treatment and Prophylaxis:<\/b> (2 months and older) initial 75 mg\/kg or 2 g\/m(2) ORALLY<\/li><li><b>Meningococcal meningitis; Treatment and Prophylaxis:<\/b> (2 months and older) maintenance, 150 mg\/kg\/day or 4 g\/m(2)\/day ORALLY divided into 4 to 6 doses, every 24 hours; MAX 6 g every 24 hours<\/li><li><b>Nocardiosis:<\/b> (2 months and older) initial 75 mg\/kg or 2 g\/m(2) ORALLY<\/li><li><b>Nocardiosis:<\/b> (2 months and older) maintenance, 150 mg\/kg\/day or 4 g\/m(2)\/day ORALLY divided into 4 to 6 doses, every 24 hours; MAX 6 g every 24 hours<\/li><li><b>Rheumatic fever, Recurrent; Prophylaxis:<\/b> (27 kg or less) 500 mg ORALLY once a day (guideline dosing)<\/li><li><b>Rheumatic fever, Recurrent; Prophylaxis:<\/b> (greater than 27 kg) 1 g ORALLY once a day (guideline dosing)<\/li><li><b>Rheumatic fever, Recurrent; Prophylaxis:<\/b> (less than 30 kg) 500 mg ORALLY every 24 hours (manufacturer dosing)<\/li><li><b>Rheumatic fever, Recurrent; Prophylaxis:<\/b> (greater than 30 kg) 1 g ORALLY every 24 hours (manufacturer dosing)<\/li><li><b>Toxoplasma encephalitis:<\/b> (2 months and older) initial 75 mg\/kg or 2 g\/m(2) ORALLY (manufacturer dosing)<\/li><li><b>Toxoplasma encephalitis:<\/b> (2 months and older) maintenance, 150 mg\/kg\/day or 4 g\/m(2)\/day ORALLY divided into 4 to 6 doses, every 24 hours; MAX 6 g every 24 hours (manufacturer dosing)<\/li><li><b>Toxoplasma encephalitis:<\/b> (acquired toxoplasmosis in children with HIV) 25 to 50 mg\/kg (MAX 1000 to 1500 mg\/dose) ORALLY 4 times daily plus pyrimethamine 2 mg\/kg (MAX 50 mg) ORALLY once daily for 3 days, then 1 mg\/kg  (MAX 25 mg) ORALLY once daily PLUS leucovorin 10 to 25 mg ORALLY daily; continue for at least 6 weeks, followed by secondary prophylaxis (guideline dosing)<\/li><li><b>Trachoma:<\/b> (2 months and older) initial 75 mg\/kg or 2 g\/m(2) ORALLY<\/li><li><b>Trachoma:<\/b> (2 months and older) maintenance, 150 mg\/kg\/day or 4 g\/m(2)\/day ORALLY divided into 4 to 6 doses, every 24 hours; MAX 6 g every 24 hours<\/li><li><b>Urinary tract infectious disease:<\/b> (2 months and older) initial 75 mg\/kg or 2 g\/m(2) ORALLY<\/li><li><b>Urinary tract infectious disease:<\/b> (2 months and older) maintenance, 150 mg\/kg\/day or 4 g\/m(2)\/day ORALLY divided into 4 to 6 doses, every 24 hours; MAX 6 g every 24 hours<\/li><\/ul>"},{"id":"cba2s1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> use caution<\/li><li><b>hepatic impairment:<\/b> use caution<\/li><li><b>dosing by blood levels:<\/b> most infections, 5 to 15 mg\/100 mL (free sulfonamide); serious infections, 12 to 15 mg\/100 mL (free sulfonamide); maximum levels, 20 mg\/100 mL (total sulfonamide)<\/li><li><b>protein calorie malnutrition (pediatrics):<\/b> reduce the dose or prolong the dosing schedule due to increased exposure<\/li><\/ul>"},{"id":"cba2s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acute otitis media, Due to Haemophilus influenzae, in combination with penicillin<\/li><li>Chancroid<\/li><li>Congenital toxoplasmosis; Adjunct<\/li><li>Haemophilus influenzae meningitis, In combination with parenteral streptomycin; Adjunct<\/li><li>Inclusion conjunctivitis<\/li><li>Malaria, due to chloroquine-resistant strains of Plasmodium falciparum; Adjunct<\/li><li>Meningococcal meningitis; Treatment and Prophylaxis<\/li><li>Nocardiosis<\/li><li>Rheumatic fever, Recurrent; Prophylaxis<\/li><li>Toxoplasma encephalitis<\/li><li>Trachoma<\/li><li>Urinary tract infectious disease<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>HIV infection - Toxoplasmosis; Prophylaxis<br\/>"}]},"3":{"id":"cba2s3","title":"Contraindications\/Warnings","sub":[{"id":"cba2s3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity to sulfADIAZINE or other sulfonamides<\/li><li>infants less than 2 months (except congenital toxoplasmosis)<\/li><li>pregnant women at term<\/li><li>breast feeding<\/li><\/ul>"},{"id":"cba2s3b10","title":"Precautions","mono":"<ul><li>impaired renal or hepatic function<\/li><li>patients with glucose-6-phosphate dehydrogenase deficiency<\/li><\/ul>"},{"id":"cba2s3b11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"cba2s3b12","title":"Breast Feeding","mono":"<ul><li>WHO: Avoid breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"cba2s4","title":"Drug Interactions","sub":{"0":{"id":"cba2s4b13","title":"Contraindicated","mono":"<ul>Methenamine (theoretical)<\/ul>"},"2":{"id":"cba2s4b15","title":"Moderate","mono":"<ul><li>Acetohexamide (probable)<\/li><li>Cyclosporine (probable)<\/li><\/ul>"}}},"5":{"id":"cba2s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Rash<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain, Diarrhea, Nausea, Vomiting<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Aplastic anemia, Hemolytic anemia, Leukopenia, Thrombocytopenia<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Renal:<\/b>Crystalluria<\/li><\/ul>"},"6":{"id":"cba2s6","title":"Drug Name Info","sub":{"2":{"id":"cba2s6b19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Sulfonamide<\/li><\/ul>"},"3":{"id":"cba2s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"cba2s6b21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"cba2s7","title":"Mechanism Of Action","mono":"SulfADIAZINE is a antibacterial agent of the sulfonamide class. SulfADIAZINE exerts antibacterial activity by competitive inhibition of bacterial synthesis of folic acid (pteroylglutamic acid) from aminobenzoic acid <br\/>"},"8":{"id":"cba2s8","title":"Pharmacokinetics","sub":[{"id":"cba2s8b23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 4 hours<\/li><li>Bioavailability, Oral: well absorbed from gastrointestinal tract<\/li><\/ul>"},{"id":"cba2s8b24","title":"Distribution","mono":"<ul><li>Protein binding: 38% to 48%<\/li><li>0.29 L\/kg<\/li><\/ul>"},{"id":"cba2s8b25","title":"Metabolism","mono":"<ul><li>Liver: extensive<\/li><li>Acetylated sulfADIAZINE: inactive (major)<\/li><\/ul>"},{"id":"cba2s8b26","title":"Excretion","mono":"<ul><li>Bile: Minor amount, % changed unknown<\/li><li>Renal: Extensive, 15% to 40% changed<\/li><li>Renal clearance: 0.55 mL\/min\/kg<\/li><\/ul>"},{"id":"cba2s8b27","title":"Elimination Half Life","mono":"7 and 16.8 hours <br\/>"}]},"9":{"id":"cba2s9","title":"Administration","mono":"<b>Oral<\/b><br\/>take each oral dose with 8 ounces of water and consume additional water at frequent intervals throughout the day <br\/>"},"10":{"id":"cba2s10","title":"Monitoring","mono":"<ul><li>free sulfonamide blood levels; range, 5 to 15 mg\/100 mL may be indicative of efficacy for most infections<\/li><li>free sulfonamide blood levels; range, 12 to 15 mg\/100 mL may be indicative of efficacy for serious infections<\/li><li>serum sulfADIAZINE levels; periodically in patients with serious infections<\/li><li>resolution of sign and symptoms of infection may be indicative of efficacy<\/li><li>total serum sulfonamide levels; 20 mg\/100 mL may be indicative of toxicity<\/li><li>CBC; frequently during treatment<\/li><li>urinalysis with microscopic examination; frequently during treatment<\/li><\/ul>"},"11":{"id":"cba2s11","title":"How Supplied","mono":"<b>Generic<\/b><br\/>Oral Tablet: 500 MG<br\/>"},"12":{"id":"cba2s12","title":"Toxicology","sub":[{"id":"cba2s12b31","title":"Clinical Effects","mono":"<b>SULFONAMIDES<\/b><br\/>OVERDOSE: Data limited. Effects may be an extension of adverse events reported with sulfonamides. Methemoglbinemia has been reported after overdose. ADVERSE EVENTS: Adverse reactions to sulfonamides can involve nearly every organ system; many effects appear to be hypersensitivity reactions, and are dose related. DERMATOLOGIC: Various dermatological reactions, including rash, pruritus, erythema nodosum, and quite severe and often fatal erythema multiforme of the Stevens-Johnson type have been reported. Lyell's Syndromes are usually associated with the use of a long-acting sulfonamides. GASTROINTESTINAL: Nausea and vomiting are common. HYPERSENSITIVITY REACTION: Transient myopia, conjunctivitis, hepatic injury, and keratitis may occur in association with a hypersensitivity reaction. NEUROLOGIC: Headache, depression, and hallucinations have been reported with therapy.  <br\/>"},{"id":"cba2s12b32","title":"Treatment","mono":"<b>SULFONAMIDES <\/b><br\/><ul><li>Decontamination: Activated charcoal.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Hypersensitivity reaction: For signs and symptoms of anaphylaxis administer oxygen, establish an airway, and give epinephrine and diphenhydramine as indicated.<\/li><li>Hypotensive episode: IV isotonic fluids at 10 to 20 mL\/kg, dopamine, norepinephrine.<\/li><li>Methemoglobinemia: Obtain a methemoglobin level. Treat symptomatic methemoglobinemia (usually at methemoglobin levels above 20% to 30%) with methylene blue and oxygen therapy.<\/li><li>Seizure: Seizures have been reported infrequently. Give benzodiazepines, barbiturates as indicated.<\/li><li>Monitoring of patient:  Obtain a baseline CBC, electrolytes including glucose level and hepatic enzymes and renal function tests.<\/li><\/ul>"},{"id":"cba2s12b33","title":"Range of Toxicity","mono":"<b>SULFONAMIDES<\/b><br\/>TOXICITY: Methemoglobinemia has been reported after ingestion of 15 g sulfamethoxazole. Many of the adverse effects related to sulfonamides are hypersensitivity reactions, that develop at therapeutic doses.  The incidence of adverse effects increases with higher doses. THERAPEUTIC DOSE: Varies by agent.<br\/>"}]},"13":{"id":"cba2s13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause diarrhea or nausea.<\/li><li>Patient should report signs\/symptoms of blood dyscrasia such as unusual bruising\/bleeding, rash, fever, or sore throat.<\/li><li>Advise patient to maintain adequate hydration during therapy to prevent crystalluria and formation of renal stones.<\/li><\/ul>"}}}